Cytena has established a subsidiary, Cytena Bioprocess Solutions Taiwan. Cytena Bioprocess Solutions is developing an innovative technology, which aims to enable considerable reductions in time and increases in efficiency for cell line development. 
 
“With the new R&D focused company, we want to further strengthen our global market position and open up new application areas and target markets. Our team in Taipei will enable us to be even closer to our Asian partners and use local R&D and production resources,” says Dr. Jonas Schoendube, CEO of Cytena in Germany.
 
Cytena Bioprocess Solutions will focus on providing bioprocess solutions for pharmaceutical companies and leading research institutes. These solutions are based on a microbioreactor called C.Bird. The C.Bird is the first microbioreactor to combine early stage cell culture screening, monitoring and optimization. 
 
“It is fantastic to be working with Cytena to bring to market a new leading-edge technology for cell line development. By establishing a site in Asia, Cytena will build new connections and enable fast delivery of our products to our global customers,” said Charles Tsai, CEO of Cytena Bioprocess Solutions.